Most of the cultured scleroderma fibroblasts have been reported to be myofibroblasts that have the ability to express a smooth muscle actin (aSMA). It is reported that, in human lung fibroblasts, aSMA is induced by transforming growth factor-b (TGF-b), which requires focal adhesion kinase (FAK) phosphorylation on its Tyr-397 site. In this study, we investigated how aSMA expression is upregulated in cultured scleroderma fibroblasts. 4-amino-5-(4-chlorophenyl)-7-(butyl)pyrazolo [3,4-d]pyrimidine, which is a pharmacologic inhibitor of FAK/Src, markedly diminished upregulated aSMA expression in scleroderma fibroblasts as well as in normal fibroblasts stimulated with TGF-b. Likewise, aSMA expression was significantly reduced in sclerderma fibroblasts transfected with kinasedeficient FAK mutant. FAK phosphorylation levels on Tyr-397 in scleroderma fibroblasts were significantly higher than those in normal fibroblasts. Both aSMA expression and FAK phosphorylation levels in scleroderma fibroblasts were markedly diminished by the treatment with TGF-b antisense oligonucleotide. These results indicate that the constitutive phosphorylation of FAK, which is possibly because of the autocrine TGF-b signaling, may play an important role in aSMA expression in scleroderma fibroblasts.
Scleroderma is an autoimmune disease characterized by the dual features of a non-inflammatory microvasculopathy and excess extracellular matrix (ECM) accumulation in the skin and internal organs. Fibroblasts derived from the affected skin areas of scleroderma patients are considered to be in an activated state, synthesizing the increased amounts of connective tissue components, mainly collagens I, III (LeRoy, 1974; Uitto et al, 1979; Jimenez et al, 1986) and VI (Peltonen et al, 1990) , fibronectin (Fleischmajer et al, 1981; Kinsella et al, 1989) , and proteoglycans (Buckingham et al, 1983) . Moreover, many of the characteristics of scleroderma fibroblasts resemble those of healthy fibroblasts exposed to transforming growth factor-b (TGF-b) (Massague, 1990) , suggesting that the scleroderma phenotype may be a result of activation by an autocrine TGF-b loop.
Smooth muscle-actin (SMA)-positive fibroblasts (myofibroblasts) are found in scleroderma and in a number of other fibrotic conditions (Sappino et al, 1990) . Ludwicka et al (1992) have identified myofibroblasts from bronchoalveolar lavage of scleroderma patients. Myofibroblasts also appear transiently in wound healing (Darby et al, 1990) . Additionally, cultured fibroblasts from affected skin of scleroderma patients (LeRoy, 1974) , from keloids (Uitto et al, 1985) , and from phenytoin-induced gingival hyperplasia (Hassell et al, 1976) continue to exhibit an abnormal phenotype even after several passages in culture. Lastly, in situ hybridization studies showed that not all but rather certain distinguishable fibroblasts in keloids (Kahari et al, 1988) and in affected scleroderma skin (Peltonen et al, 1991) contain high levels of collagen mRNA. Kirk et al (1995) suggested that the myofibroblast phenotype might correspond to this ''activated fibroblast'' phenotype found in systemic sclerosis. Myofibroblasts have a high synthetic capacity for ECM proteins (Ignotz and Massagué , 1986; Zhang et al, 1994) , growth factors/cytokines (Finlay et al, 2000) , growth factor receptors (Thannickal et al, 1998) , integrins (Heino et al, 1989) , and oxidants (Thannickal and Fanburg, 1995) .
The presence of myofibroblasts appears to be a consistent finding in the pathology of human fibrotic diseases involving diverse organ systems such as the lung, liver, and kidney (Border and Noble, 1994) . Thus, persistent myofibroblast proliferation and/or survival represent a pathologic repair process that can result in aberrant architectural remodeling of tissues associated with end-stage fibrosis and organ failure.
The focal adhesion kinase (FAK) is a protein tyrosine kinase (PTK) that is regulated by multiple extracellular stimuli (Schaller et al, 1994; Schwartz et al, 1995) . Cell adhesion to the ECM proteins, e.g., fibronectin or collagen, via their receptors, the integrins (Hynes, 1992) , induces the tyrosine phosphorylation of FAK and stimulation of its enzymatic Abbreviations: aSMA, a smooth muscle actin; ECM, extracellular matrix; FAK, focal adhesion kinase; PP2, 4-amino-5-(4-chlorophenyl)-7-(butyl)pyrazolo [3,4-d] activity (Burridge et al, 1992; Guan and Shalloway, 1992; Hanks et al, 1992; Kornberg et al, 1992; Lipfert et al, 1992) . Treatment of cells with a number of agents including growth factors, neuropeptides, and lysophosphatidic acid can induce the phosphorylation of FAK on tyrosine (Zachary et al, 1992; Kumagai et al, 1993; Sinnett-Smith et al, 1993; Barry and Critchley, 1994; Chrzanowska-Wodnicka and Burridge, 1994; Matsumoto et al, 1994; Polte et al, 1994; Rankin and Rozengurt, 1994; Ridley and Hall, 1994; Seufferlein and Rozengurt, 1994) . Thus multiple stimuli, acting on distinct cell surface receptors that trigger discrete cytoplasmic signaling pathways, converge to induce a common response, the tyrosine phosphorylation of FAK. Like other PTK, tyrosine phosphorylation of FAK plays an important role in regulating signaling. Six tyrosine residues within FAK have been identified as sites of phosphorylation. The major site of autophosphorylation is Tyr 397 (Chan et al, 1994; Schaller et al, 1994; Calalb et al, 1995; Eide et al, 1995) . Moreover, Thannickal et al (2003) showed that tyrosine phosphorylation of FAK at Tyr 397 site is involved in myofibroblast differentiation induced by TGF-b using human lung fibroblasts. This study was undertaken to examine a possible role of autocrine TGF-b signaling and FAK phosphorylation in myofibroblast differentiation of scleroderma fibroblasts.
Results
Comparison of levels of aSMA expression between cultured normal and scleroderma fibroblasts We compared the constitutive aSMA expression levels between normal and scleroderma fibroblasts by immunoblotting. Consistent with previous reports (Peltonen et al, 1991) , scleroderma fibroblasts expressed increased levels of aSMA protein (9.9-fold. Fig 1) . Six separate lanes for normal and scleroderma fibroblast cultures represent six separate primary isolates from different individuals.
Effect of a pharmacologic FAK/Src inhibitor on the TGF-b-mediated aSMA protein upregulation in normal fibroblasts and on the constitutive overexpression of aSMA protein in scleroderma dermal fibroblasts We investigated the effect of 4-amino-5-(4-chlorophenyl)-7-(butyl)pyrazolo [3,4-d] pyrimidine (PP2), which is a pharmacologic FAK/Src inhibitor, and TGF-b on the expression of aSMA in normal and scleroderma dermal fibroblasts by immunoblotting. As shown in Fig 2A, in normal fibroblasts, PP2 slightly reduced the basal level of aSMA expression and TGF-b induced upregulation of aSMA expression (4.2-fold), which was inhibited by PP2. In contrast, PP2 significantly reduced the basal level of aSMA expression in scleroderma fibroblasts. The inhibitory effect of PP2 on aSMA expression induced by TGF-b was concentrationdependent both in normal and scleroderma fibroblasts. Next, we examined the effect of PP2 and TGF-b on the expression of aSMA in normal and scleroderma dermal fibroblasts by immunofluorescence (Fig 2B) . The majority of untreated normal fibroblasts were smaller and expressing less amounts of aSMA than that of untreated scleroderma fibroblasts. PP2 blocks cell hypertrophy and formation of actin stress fibers induced by TGF-b1 or observed in untreated scleroderma fibroblasts. The treatment of PP2 had little effect on the size or basal aSMA expression levels in normal fibroblasts, whereas it markedly reduced the size and basal aSMA expression in scleroderma fibroblasts. The stimulation with TGF-b turned normal fibroblasts into larger cells expressing much more aSMA, which looked like scleroderma fibroblasts. But, the treatment with TGF-b brought about little change in scleroderma fibroblasts. PP2 had an inhibitory effect on the size and aSMA expression levels both in normal and scleroderma fibroblasts stimulated with TGF-b. These findings suggested that the upregulation of aSMA expression observed in normal fibroblasts treated with TGF-b or in untreated scleroderma fibroblasts requires FAK activation.
Comparison of FAK phosphorylation levels between cultured normal and scleroderma fibroblasts We examined the basal phosphorylation levels of FAK (Tyr-397 site) in cultured normal and scleroderma dermal fibroblasts by immunoblotting using a site-specific antibody. As shown in Fig 3 , the basal phosphorylation levels of FAK in scleroderma fibroblasts were significantly higher than those in normal fibroblasts (1.8-fold). Four separate lanes for normal and scleroderma fibroblast cultures represent four separate primary isolates from different individuals. Comparison of levels of a smooth muscle actin (aSMA) expression between cultured normal and scleroderma fibroblasts. Whole-cell lysates for aSMA were electrophoresed through a 10% polyacrylamide gel, transferred to a nitrocellulose membrane, and probed with antiaSMA antibodies. After stripping, the levels of b-actin were determined by anti-b-actin antibody. One representative of five independent experiments is shown in the upper panel. Six separate lanes for normal and scleroderma fibroblast cultures represent six separate primary isolates from different individuals. The aSMA levels quantitated by scanning densitometry densitometry and corrected for the levels of bactin in the same samples are shown relative to the levels in normal fibroblasts (1.0). Data are expressed as the mean AE SD of five independent experiments (lower panel). Ã po0.05, as compared with the value in normal fibroblasts.
TGF-b induces FAK phosphorylation on Tyr-397 site in normal fibroblasts We investigated whether TGF-b induces FAK phoshorylation on Tyr-397 site using normal dermal fibroblasts. Like a previous report using lung fibroblasts, TGF-b induced FAK phosphorylation in dermal fibroblasts in a time-dependent manner (2.2-fold, Fig 4) . FAK phosphorylation level started to increase about 3 h after the stimulation and sustained for a relatively long duration (about 24 h).
Transfection of kinase-deficient FAK diminished both TGF-b-mediated aSMA protein upregulation in normal fibroblasts and constitutive overexpression of aSMA protein in scleroderma dermal fibroblasts To further confirm that phosphorylation of FAK, especially at Tyr-397 site, is required for the upregulated expression of aSMA observed in the TGF-b stimulated normal fibroblasts and untreated scleroderma fibroblasts, both normal and scleroderma fibroblasts were transfected with a mutant FAK (Y397F-FAK) or an empty vector, and aSMA expression was determined by immunoblotting. In normal fibroblasts transfected with Y397F-FAK, the basal level of aSMA expression was almost the same as that of mock transfectants, although aSMA expression in response to TGF-b1 was significantly diminished in a concentration-dependent manner (Fig 5) . In scleroderma fibroblasts transfected with mutant FAK (Y397F-FAK) without stimulation, the basal level of aSMA expression was significantly diminished (Fig 5) . Human dermal fibroblasts were serum-starved for 24 h and pre-treated with the indicated doses of PP2 for 1 h prior to the addition of 2 ng per mL of TGF-b for 24 h. Cell lysates were then obtained and subjected to SDS-PAGE followed by immunoblotting with antibodies against aSMA and b-actin. Levels of b-actin are shown as a loading control. The bands shown represent two primary isolates from one normal donor and one scleroderma patient. One representative of five independent experiments is shown in the upper panel. The aSMA levels quantitated by scanning densitometry and corrected for the levels of b-actin in the same samples are shown relative to the level in untreated normal cells (1.0). Data are expressed as the mean AE SD of five independent experiments (lower panel). Ã po0.05, as compared with the value in untreated scleroderma fibroblasts. #po0.05, as compared with the value in untreated normal fibroblasts. (B) The shape and aSMA expression were investigated with immunofluorescence analysis using human normal and scleroderma fibroblasts as described in Materials and Methods. PP2 blocks cell hypertrophy and formation of actin stress fibers induced by TGF-b1 or observed in untreated scleroderma fibroblasts. a, untreated normal fibrolblasts. b, normal fibroblasts treated with PP2 (20 mM). c, normal fibroblasts treated with 2 ng per mL TGF-b1. d, normal fibroblasts treated with both PP2 (20 mM) and 2 ng per mL TGFb1. e, untreated scleroderma fibroblasts. f, scleroderma fibroblasts treated with PP2 (20 mM). g, normal fibroblasts treated with 2 ng per mL TGF-b1. h, scleroderma fibroblasts treated with both PP2 (20 mM) and 2 ng per mL TGF-b1.
Figure 3
Comparison of focal adhesion kinase (FAK) phosphorylation levels between cultured normal and scleroderma fibroblasts. Whole-cell lysates were electrophoresed through a 10% polyacrylamide gel, transferred to a nitrocellulose membrane, and probed with anti-sitespecific p-FAK (Try 397) antibodies. After stripping, total levels of FAK were determined by anti-FAK antibody. One representative of five independent experiments is shown in the upper panel. Four separate lanes for normal and scleroderma fibroblast cultures represent four separate primary isolates from different individuals. The p-FAK levels quantitated by scanning densitometry densitometry and corrected for the levels of total FAK in the same samples are shown relative to the levels in normal fibroblasts (1.0). Data are expressed as the mean AE SD of five independent experiments (lower panel). Ã po0.05, as compared with the value in normal fibroblasts. THE JOURNAL OF INVESTIGATIVE DERMATOLOGY Together, these results indicate that the autophosphorylation of FAK on Tyr-397 is required for the myofibroblast differentiation induced by TGF-b1 in normal fibroblasts, and that observed in scleroderma fibroblasts.
The treatment with TGF-b1 antisense oligonucleotide significantly reduced the level of aSMA expression and FAK phosphorylation on Tyr-397 in scleroderma fibroblasts To examine the possibility that the upregulated levels of aSMA expression and FAK phosphorylation on Tyr-397 in scleroderma fibroblasts are because of the autocrine TGF-b signaling, we investigated the effect of TGF-b1 antisense oligonucleotide on the levels of aSMA expression and FAK phosphorylation on Tyr-397. As shown in Fig 6A, the treatment with TGF-b1 antisense oligonucleotide did not significantly reduce aSMA expression in normal fibroblasts. In contrast, TGF-b1 antisense oligonucleotide markedly reduced aSMA expression in scleroderma fibroblasts. The treatment with TGF-b1 sense oligonucleotide had no effect on aSMA expression. The FAK phosphorylation levels in scleroderma fibroblasts were significantly diminished by the treatment with TGF-b1 antisense oligonucleotide, whereas those in normal fibroblasts decreased only slightly (Fig 6B) . These results imply that the upregulated levels of aSMA expression and FAK phosphorylation on Tyr-397 in scleroderma fibroblasts are because of the autocrine TGF-b signaling.
The treatment with RGD (Arg-Gly-Asp) containing peptide significantly reduced aSMA expression in scleroderma fibroblasts Previous studies showed that TGF-b-mediated upregulation of aSMA expression is at least partially through the interactions between ECM and integrins (Thannickal et al, 2003) . We examined whether RGD-containing peptide, which is an antagonist of integrin function, could reduce aSMA expression in scleroderma fibroblasts that have been reported to overexpress both ECM and integrins (Fleischmajer et al, 1981; Kinsella et al, 1989; Asano et al, 2004) . As shown in Fig 7, the treatment with RGD-containing peptide did not significantly reduce aSMA expression in normal fibroblasts. In contrast, RGDcontaining peptide markedly reduced aSMA expression in scleroderma fibroblasts. The treatment with RGE (ArgGly-Glu)-containing peptide had no inhibitory effect on aSMA expression. Transfection of kinase-deficient focal adhesion kinase (FAK) diminished both the transforming growth factor-b (TGF-b)-mediated a smooth muscle actin (aSMA) protein upregulation in normal fibroblasts and the constitutive overexpression of aSMA protein in scleroderma fibroblasts. Human dermal fibroblasts were transiently transfected with either empty vector or with the indicated doses of kinase-deficient FAK mutant (Y397F-FAK, substitution of Phe for Tyr-397). After incubation overnight, the transfected cells were either treated or untreated with 2 ng per mL TGF-b1 for 48 h. Cell lysates were obtained and subjected to SDS-PAGE followed by immunoblotting with antibodies against aSMA and b-actin. Levels of b-actin are shown as a loading control. The bands shown represent two primary isolates from one normal donor and one scleroderma patient. One representative result of five independent experiments is shown. The aSMA levels quantitated by scanning densitometry densitometry and corrected for the levels of b-actin in the same samples are shown relative to the level in mock-transfected normal cells (1.0). Data are expressed as the mean AE SD of five independent experiments (lower panel). Ã po0.05, as compared with the value in untreated scleroderma fibroblasts. #po0.05, as compared with the value in mock-transfected normal fibroblasts.
Discussion
It is well established that most cultured scleroderma fibroblasts express aSMA even after several passages. Little is known, however, about how cultured scleroderma fibroblasts maintain the expression of aSMA.
aSMA can be induced by exogenous TGF-b in cultured normal fibroblasts. Therefore, there is a good possibility that the autocrine TGF-b loop contributes to the maintenance of aSMA expression in scleroderma fibroblasts. In this study, we showed that TGF-b1 antisense oligonucleotide significantly reduced the level of aSMA expression, which seems to support the possibility described above.
A previous report suggested that aSMA expression was increased through the interaction between integrins and ECM, especially fibronectin, via phosphorylation of FAK (Thannickal et al, 2003) . Both integrins and fibronectin have been reported to be upregulated in scleroderma (Fleischmajer et al, 1981; Kinsella et al, 1989; Asano et al, 2004) . We assumed that increased interaction between integrins and ECM leads to overexpression of aSMA in scleroderma fibroblasts through the enhancement of FAK phosphorylation. In this study, we showed that FAK phosohorylation is constitutively upregulated in scleroderma fibroblasts and that a dominant-negative mutant form of FAK markedly reduced aSMA expression in scleroderma fibroblasts. In addition, we demonstrated that RGD-containing peptide, which is an antagonist of integrin function, significantly reduced aSMA expression in scleroderma fibroblasts. All of these The treatment with transforming growth factor-b1 (TGF-b1) antisense oligonucleotide significantly reduced the levels of a smooth muscle actin (aSMA) expression and focal adhesion kinase (FAK) phosphorylation on Tyr-397 in scleroderma fibroblasts. (A) The effect of TGF-b1 antisense oligonucleotide on aSMA protein expression was investigated by immunoblotting (upper panel). Normal and scleroderma fibroblasts were treated with TGF-b1 antisense oligonucleotide for 48 h. The bands shown represent four primary isolates from two normal donors and two scleroderma patients. One representative of five independent experiments is shown. The aSMA levels quantitated by scanning densitometry densitometry and corrected for the levels of bactin in the same samples are shown relative to those in normal fibroblasts treated with sense oligonucleotide (1.0). Data are expressed as the mean AE SD of five independent experiments (lower panel). Ã po0.05 versus control cells treated with TGF-b1 sense oligonucleotide. (B) The effect of TGF-b1 antisense oligonucleotide on FAK phosphorylation levels was investigated by immunoblotting (upper panel). Normal and scleroderma fibroblasts were treated with TGF-b1 antisense oligonucleotide for 48 h. The bands shown represent four primary isolates from two normal donors and two scleroderma patients. One representative of five independent experiments is shown. The p-FAK levels quantitated by scanning densitometry densitometry and corrected for the levels of total FAK in the same samples are shown relative to those in normal fibroblasts treated with sense oligonucleotide (1.0). Data are expressed as the mean AE SD of five independent experiments (lower panel). Ã po0.05 versus control cells treated with TGF-b1 sense oligonucleotide.
Figure 7
The treatment with RGD (Arg-Gly-Asp)-containing peptides significantly reduced a smooth muscle actin (aSMA) expression in scleroderma fibroblasts. The effect of RGD-containing peptides on aSMA protein expression was investigated by immunoblotting (upper panel). Normal and scleroderma fibroblasts were treated with RGD-or RGE (Arg-Gly-Glu)-containing peptides for 48 h. The bands shown represent four primary isolates from two normal donors and two scleroderma patients. One representative of five independent experiments is shown. The aSMA levels quantitated by scanning densitometry densitometry and corrected for the levels of b-actin in the same samples are shown relative to those in normal fibroblasts treated with RGE-containing peptides (1.0). Data are expressed as the mean AE SD of five independent experiments (lower panel). Ã po0.05 versus control cells treated with RGE-containing peptides.
findings support the notion that the interaction between integrins and ECM leads to overexpression of aSMA in scleroderma fibroblasts through the enhancement of FAK phosphorylation.
In conclusion, we demonstrated that the autocrine TGF-b signaling and the interaction between integrins and ECM contribute to the upregulation of aSMA expression in cultured scleroderma fibroblasts. These results suggested that various kinds of agents that inhibit autocrine TGF-b signaling or the interaction between integrins and ECM could be used as a therapeutic intervention for scleroderma by turning back scleroderma fibroblasts abnormally overexpressing aSMA into approximately normal fibroblasts less expressing aSMA.
Materials and Methods
Reagents Recombinant human TGF-b1 was obtained from R&D Systems (Minneapolis, Minnesota). PP2 was from Calbiochem (La Jolla, California). Anti-b-actin, anti-aSMA antibodies, synthetic RGD/RGE containing peptides were purchased from Sigma (St. Louis, Missouri). The luciferase assay kit was purchased from Promega (Madison, Wisconsin). Phosphorylation-specific antibody to Tyr-397-FAK was from BIOSOURCE International (Carmillo, California). Antibody for FAK was purchased from Upstate Biotechnology (Lake Placid, New York). FuGENE 6 was obtained from Roche Diagnostics (Indianapolis, Indiana).
Cell cultures Human dermal fibroblasts were obtained by skin biopsy from the affected areas (dorsal forearm) of eight patients with diffuse cutaneous scleroderma and o2 y of skin thickening (Ihn et al, 2001) . Control fibroblasts were obtained by skin biopsy from eight healthy donors. Institutional approval and written informed consent were obtained from all subjects. The study was conducted according to the Declaration of Helsinki principles. Control donors were matched with each scleroderma patient for age, sex, and biopsy site, and control and patient samples were processed in parallel. Primary explant cultures were established in 25-cm 2 culture flasks in modified eagle's medium (MEM) with 10% fetal calf serum (FCS), 2 mM L-glutamine, and 50 mg per mL amphotericin. Fibroblast cultures independently isolated from different individuals were maintained as monolayers at 371C in 95% air, 5% CO 2 , and studied between the third and sixth subpassages.
Cell lysis and Immunoblotting Fibroblasts were grown to subconfluence in MEM with 10% FCS. After 24 h serum starvation, cells were solubilized in lysis buffer (1% Triton X-100 in 50 mM TrisHCl (pH 7.4), 150 mM NaCl, 3 mM MgCl 2 , 1 mM CaCl 2 containing 10 mg per mL leupeptin, pepstatin, aprotinin, 1 mM PMSF, and 1 mM Na 3 VO 4 ). The loading amount was adjusted by the protein concentrations of cell lysate determined by a Bio-Rad protein assay (Hercules, California), as recommended by the manufacturer.
Proteins were subjected to SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. Membranes were incubated overnight with anti-aSMA antibody, anti-FAK antibody, or anti-pFAK antibody (1:1000 dilution), washed, and incubated with horseradish peroxidase-conjugated secondary antibodies for 60 min. After washing, visualization was performed by enhanced chemiluminescence (Amersham Pharmacia Biotech, Arlington Heights, Illinois). As a loading control, immunoblotting was also performed using antibodies against b-actin.
Immunofluorescence Immunofluorescence analysis was performed as described previously . In brief, normal and scleroderma fibroblasts were cultured in four-well tissue culture chamber slides. After cells were placed under conditions of serum starvation for 24 h and treated with 2 ng per mL TGF-b for an additional 48 h, the medium was removed and the cells were washed with PBS and fixed in 3.7% formaldehyde/PBS for 10 min. After two washes with PBS, cells were incubated for 30 min in PBS containing 10% FBS. Cells were permeabilized with 0.5% Triton-X. An antibody against aSMA was added and the slides were incubated for 1 h at 371C. After three washes, a fluorescein-conjugated secondary antibody was added and the slides were incubated for 1 h at 371C.
Treatment of dermal fibroblasts with TGF-b1 antisense oligonucleotides We used a TGF-b1 18-mer antisense oligonucleotide (GAGGGCGGCATGGGGAGG), which overlaps the promoter and transcriptional start site of the TGF-b1 gene. This same sequence, which is specific for the TGF-b1 isoform, has been found to be sufficient to block TGF-b1 transcription in vitro (Falanga et al, 1998; Ihn et al, 2001 ) and in vivo (Brunet et al, 1995) . A sense oligonucleotide was also used as control.
Fibroblasts were grown to confluence and the culture medium was removed, washed with MEM to remove excess TGF-b1, and replaced with serum-free MEM. Then antisense or sense TGF-b1 oligonucleotide was added, and cell lysates were obtained 48 h later.
Plasmids The mammalian expression plasmid pKH3 encoding mutant FAK (substitution of Phe for Tyr-397; Y397F-FAK) was a kind gift from Dr Hong-Chen Chen (Institute for Biochemistry, National Chung Hsing University, Taiwan) and has been described previously (Chen et al, 1996) . Plasmids used in transient transfection assays were purified twice on CsCl gradients, as described previously. At least two different plasmid preparations were used for each experiment.
Transient transfection Fibroblasts were grown to 50% confluence in 100 mm dishes. After 24 h incubation with serum-free medium, cultures were transfected with the indicated doses of empty vector or kinase-deficient FAK mutant .
Statistical analysis Data presented as bar graphs are the means AE SD of at least three independent experiments. Statistical analysis was performed by the Mann-Whitney U test. p values less than 0.05 were considered significant.
